Bis-aryl Urea Derivatives as Potent and Selective LIM Kinase (Limk) Inhibitors
Citations Over TimeTop 10% of 2015 papers
Abstract
The discovery/optimization of bis-aryl ureas as Limk inhibitors to obtain high potency and selectivity and appropriate pharmacokinetic properties through systematic SAR studies is reported. Docking studies supported the observed SAR. Optimized Limk inhibitors had high biochemical potency (IC50 400-fold), potent inhibition of cofilin phosphorylation in A7r5, PC-3, and CEM-SS T cells (IC50 < 1 μM), and good in vitro and in vivo pharmacokinetic properties. In the profiling against a panel of 61 kinases, compound 18b at 1 μM inhibited only Limk1 and STK16 with ≥80% inhibition. Compounds 18b and 18f were highly efficient in inhibiting cell-invasion/migration in PC-3 cells. In addition, compound 18w was demonstrated to be effective on reducing intraocular pressure (IOP) on rat eyes. Taken together, these data demonstrated that we had developed a novel class of bis-aryl urea derived potent and selective Limk inhibitors.
Related Papers
- → Application of Emax model to assess the potency of topical corticosteroid products(2022)4 cited
- → Establishment of a Potency Test by ELISA for a Rabies Vaccine for Animal Use in Japan(2003)15 cited
- → STANDARDIZATION OF ANTIVENINE I. A METHOD FOR DETERMINATION OF ANTILETHAL POTENCY OF HABU ANTIVENINE(1965)19 cited
- → The Experimental Study on the continuous Anti-bacterial Potency of Coptidis rhizoma extract on Cultivation of Staphylococcus species(S. aureus, S. epidermidis)(2007)1 cited
- → Potency analysis of cellular therapies: the role of molecular assays(2021)